COVID-19 and psoriasis: biologic treatment and challenges.
38
TL;DR: Reports indicated psoriatic patients on biologics were not more susceptible to COVID-19 and the severe clinical course of disease, and the available evidence suggests that patients with psoriasis without CO VID-19 can continue the biologic therapy for Psoriasis.
read more
Abstract: Background: There is concern about susceptibility of psoriatic patients on biologics to coronavirus disease 2019 (COVID-19) and its clinical coursePurpose: The aims of present review were to determine whether the biologic treatment of psoriasis increases the risk of SARS-CoV-2 infection and if biologics affect the clinical course of COVID-19 in these patientsMethods: We searched database of MEDLINE (PubMed) for key term of psoriasis biologic and COVID-19 until June 9, 2020 and all published 14 papers and an experience from Iran (10509 cases) related to the psoriatic patients on biologics and COVID-19 along with relevant papers were summarized In spite of limitation in some reports, due to some of strengths that will be discussed, all papers were included in this reviewResults: According to 8769 medical reports around 03% of psoriatic patients had COVID-19 and the rate of hospitalization was 01% No death due to COVID-19 was reported among 10509 patients Reports indicated psoriatic patients on biologics were not more susceptible to COVID-19 and the severe clinical course of diseaseConclusion: While there is not definitive controlled trial data, the available evidence suggests that patients with psoriasis without COVID-19 can continue the biologic therapy for psoriasis
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.
Joel M. Gelfand,April Armstrong,Stacie Bell,George L. Anesi,Andrew Blauvelt,Cassandra Calabrese,Erica D. Dommasch,Steve R. Feldman,Dafna D. Gladman,Dafna D. Gladman,Leon H Kircik,Leon H Kircik,Mark Lebwohl,Vincent Lo Re,George R. Martin,Joseph F. Merola,Jose U. Scher,Sergio Schwartzman,James R. Treat,Abby S. Van Voorhees,Christoph T. Ellebrecht,Justine Fenner,Anthony Ocon,Maha N. Syed,Erica J. Weinstein,Jessica Smith,George Gondo,Sue Heydon,Samantha Koons,Christopher T. Ritchlin +29 more
TL;DR: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 and what they should do if they develop CO VID-19.
50
Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge.
Zeinab Mohseni Afshar,Arefeh Babazadeh,Amirhossein Hasanpour,Mohammad Barary,Babak Sayad,Alireza Janbakhsh,Zeinab Aryanian,Zeinab Aryanian,Soheil Ebrahimpour +8 more
TL;DR: Wang et al. as mentioned in this paper focused on the various cutaneous manifestations of COVID-19 infection and found that there has been no report of skin features among CO VID-19 patients.
43
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
TL;DR: In this article , the authors describe the role of teledermatology during the COVID-19 pandemic to analyze main strengths and limitations of this tool, as well as to provide future perspectives in clinical applications.
30
Sickle cell disease and COVID-19: Susceptibility and severity.
TL;DR: The obtained results should be interpreted considering low cases from sub-Saharan people, younger age of SCD patients compared to general population, a bias toward registry of more severe form of the disease, the influence of preexisting comorbidities with multisystem organ damage in exacerbation of the COVID-19 and the fatality rate inSCD patients and the role of health socio-economic determinants.
29
Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.
TL;DR: It is suggested that biologic treatment for moderate‐to‐severe psoriasis would not pose an additional risk for COVID‐19 infection and its life‐threatening complications, even in the presence of a high frequency of cardiometabolic comorbidities, provided that all patients are informed and necessary pandemic‐directed precautions are well adopted by the patients.
27
References
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
Muthiah Vaduganathan,Orly Vardeny,Thomas Michel,John J.V. McMurray,Marc A. Pfeffer,Scott D. Solomon +5 more
TL;DR: RAAS Inhibitors in Patients with Covid-19 show low levels of renin–angiotensin-converting enzyme 2 levels and activity in humans, but the effects are still uncertain.
2K
Psoriasis Pathogenesis and Treatment.
Adriana Rendon,Knut Schäkel +1 more
TL;DR: The role of genetics, associated epigenetic mechanisms, and the interaction of the skin flora in the pathophysiology of psoriasis is described, which includes a comprehensive review of well-established widely available therapies and novel targeted drugs.
1.5K
Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.
TL;DR: PsO patients on biologics should be carefully monitored with telemedicine during COVID‐19 outbreak and early treated at home to limit hospital overwhelm and increased risk of ICU admission or death were found.
119
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment.
Paolo Gisondi,Gianluigi Zaza,Micol Del Giglio,Mattia Rossi,Valentina Iacono,Giampiero Girolomoni +5 more
59
SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.
TL;DR: Concern has risen concern among patients undergoing biologics and physicians who administer them as far as the possible increase of incidence and severity of COVID‐19 in this delicate population concerns.
56
Related Papers (5)
[...]